Matthew J. Evans
- ASSISTANT PROFESSOR Microbiology
Postdoctoral Fellow, The Rockefeller University
Ph.D., Columbia University
The hepatitis C virus (HCV) is the leading cause of liver disease in the United States. The currently employed interferon-based treatment is inadequate, as it has severe side effects and is only effective in half of the major genotype-infected individuals. The Evans lab explores the cell entry mechanisms of HCV, with the ultimate goal of uncovering novel antiviral targets and developing additional systems to study this important human pathogen. With our recent discovery that two tight junction proteins, claudin-1 and occludin (OCLN), are essential for HCV entry, we have completed the list of cell type-specific HCV cell entry factors. Although we now know all the factors required for HCV cell entry and can essentially render any mammalian cell able to support this process, we do not understand how they mediate HCV infection. Through a combination of reverse genetics, biochemistry, microscopy, and cell biology approaches we wish to define the mechanism by which each HCV cell entry factor mediates the various stages of viral entry; including recognition and binding to suitable target cells, transport across the cell surface, endocytosis, and eventual fusion within an endosome.
Watch a video featuring the Microbiology and Virology PhD Graduate School Program.
2010 - 2015
Pew Scholar in Biomedical Sciences
The Pew Charitable Trusts
Blavatnik Award for Young Scientists Finalist
New York Academy of Sciences
Sourisseau M, Goldman O, He W, Gori JL, Kiem HP, Gouon-Evans V, Evans MJ. Hepatic Cells Derived from Induced Pluripotent Stem Cells of Pigtail Macaques Support Hepatitis C Virus infection. Gastroenterology 2013 Jul;.
Goldman O, Han S, Sourrisseau M, Dziedzic N, Hamou W, Corneo B, D'Souza S, Sato T, Kotton DN, Bissig KD, Kalir T, Jacobs A, Evans T, Evans MJ, Gouon-Evans V. KDR identifies a conserved human and murine hepatic progenitor and instructs early liver development. Cell stem cell 2013 Jun; 12(6).
Sourisseau M, Michta ML, Zony C, Israelow B, Hopcraft SE, Narbus CM, Parra Martín A, Evans MJ. Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. PLoS pathogens 2013 Mar; 9(3).
García-Sastre A, Evans MJ. miR-122 is more than a shield for the hepatitis C virus genome. Proceedings of the National Academy of Sciences of the United States of America 2013 Jan;.
Mullokandov G, Baccarini A, Ruzo A, Jayaprakash AD, Tung N, Israelow B, Evans MJ, Sachidanandam R, Brown BD. High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. Nature methods 2012 Aug; 9(8).
Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America 2012 Apr;.
Ploss A, Evans MJ. Hepatitis C virus host cell entry [review]. Current opinion in virology 2012 Feb; 2(1).
Narbus CM, Israelow B, Sourisseau M, Michta ML, Hopcraft SE, Zeiner GM, Evans MJ. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. Journal of virology 2011 Nov; 85(22).
Sabo MC, Luca VC, Prentoe J, Hopcraft SE, Blight KJ, Yi M, Lemon SM, Ball JK, Bukh J, Evans MJ, Fremont DH, Diamond MS. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. Journal of virology 2011 Jul; 85(14).
Michta ML, Hopcraft SE, Narbus CM, Kratovac Z, Israelow B, Sourisseau M, Evans MJ. Species-Specific Regions of Occludin Required by Hepatitis C Virus for Cell Entry. J Virol 2010 Nov; 84(22): 11696-11708.
Dentzer TG, Lorenz IC, Evans MJ, Rice CM. Determinants of hepatitis C virus nonstructural protein 2 protease domain required for production of infectious virus. . J Virol 2009 Oct; 83(24): 12702-12713.
Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009 Feb; 457(7231): 882-886.
Eng FJ, Walewski JL, Klepper AL, Fishman SL, Desai SM, McMullan LK, Evans MJ, Rice CM, Branch AD. Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms. J Virol 2009 Jan; 83(7): 3104-3114.
Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, Keck ZY, Foung SK, Pietschmann T, Rice CM, Patel AH. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 2009 Jan; 90(1): 48-58.
Lanford RE, Evans MJ, Lohmann V, Lindenbach BD, Gale M Jr, Rehermann B, Chang KM, Lemon SM. The accelerating pace of HCV research: a summary of the 15th International Symposium on Hepatitis C Virus And Related Viruses [review]. Gastroenterology 2009 Jan; 136(1): 9-16.
Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, Charles ED, Rice CM, Dustin LB. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 2008 Dec; 48(6): 1843-1850.
Tscherne DM, Evans MJ, MacDonald MR, Rice CM. Transdominant inhibition of bovine viral diarrhea virus entry. J Virol 2008; 82(5): 2427-2436.
Stamataki Z, Coates C, Evans MJ, Wininger M, Crawford K, Dong C, Fong Y, Chien D, Abrignani S, Balfe P, Rice CM, McKeating JA, Houghton M. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007; 25(45): 7773-7784.
Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446(7137): 801-805.
Tellinghuisen T, Evans MJ, von Hahn T, You S, Rice CM. Studying hepatitis C - making the best out of a bad virus. J Virol 2007; 81(17): 8853-8867.
McMullan LK, Grakoui A, Evans MJ, Mihalik K, Puig M, Branch AD, Feinstone SM, Rice CM. Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci U.S.A. 2007; 104(8): 2879-2884.
Tscherne DM, Evans MJ, von Hahn T, Jones CT, Stamataki Z, McKeating JA, Lindenbach BD, Rice CM. Superinfection exclusion in cells infected with hepatitis C virus. J Virol 2007; 81(8): 3693-3703.
Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM. Time and temperature dependent activation for hepatitis C virus low pH triggered entry. J Virol 2006; 80(4): 1734-1741.
Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete replication of hepatitis C virus in cell culture. Science 2005; 309(5734): 623-626.
Mark-Danieli M, Laham N, Kenan-Eichler M, Castiel A, Melamed D, Landau M, Bouvier NM, Evans MJ, Bacharach E. Single point mutations in the zinc finger motifs of the human immunodeficiency virus type 1 nucleocapsid alter RNA binding specificities of the gag protein and enhance packaging and infectivity. J Virol 2005; 79(12): 7756-7767.
Evans MJ, Rice CM, Goff SP. Genetic interactions between hepatitis C virus replicons. J Virol 2004; 78(21): 12085-12089.
Evans MJ, Rice CM, Goff SP. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A 2004 Aug; 101(35): 13038-13043.
Evans MJ, Rice CM, Goff SP. RNA sequences in the Moloney murine leukemia virus genome bound by the Gag precursor protein in the yeast three-hybrid system. J Virol 2004 Jul; 78(14): 7677-7684.
Moradpour D, Evans MJ, Gosert R, Yuan Z, Blum HE, Goff SP, Lindenbach BD, Rice CM. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol 2004 Jul; 78(14): 7400-7409.
Evans MJ, Rice CM. Hepatitis C virus replicons finally get to second base [review]. Gastroenterology 2003 Dec; 125(6): 1808-1817.
Evans MJ, Gurer C, Loike JD, Wilmut I, Schnieke AE, Schon EA. Mitochondrial DNA genotypes in nuclear transfer-derived cloned sheep. Nature Genetics 1999 Sep; 23(1): 90-93.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Evans did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Annenberg Building Floor 16 Room 16-64
1468 Madison Avenue
New York, NY 10029